Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | $1.90 | +42.9% | $481.00M | +47.7% | $1.79 |
| Q1 FY26ended Mar 31, 2026 | May 12, 2026 | $1.22 | +31.2% | $376.71M | +42.2% | $1.53 |
| Q4 FY25ended Dec 31, 2025 | — | −$1.16 | −209.4% | $451.77M | +51.6% | — |
| Q3 FY25ended Sep 30, 2025 | — | $1.43 | +36.2% | $354.26M | +22.1% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.33 | +84.7% | $325.72M | +40.8% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.93 | +55.0% | $264.86M | +35.2% | — |
| Q4 FY24ended Dec 31, 2024 | — | $1.06 | +63.1% | $298.01M | +29.5% | — |
| Q3 FY24ended Sep 30, 2024 | — | $1.05 | +72.1% | $290.08M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe Halozyme Therapeutics shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| +34.3% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.72 | — | $231.35M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.60 | — | $195.88M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.65 | — | $230.04M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.61 | — | $216.03M | — | — |